肿瘤药学2018，Vol.8Issue(2)：215-218,4.DOI:10.3969/j.issn.2095-1264.2018.02.20
恩替卡韦联合肝动脉化疗栓塞术对肝癌合并乙肝患者的疗效及乙肝病毒再激活的影响
Therapeutic Effect of Nucleotide Drugs (Entecavir) Combined with TACE on Hepatic Carcinoma Patients with HBV
摘要
Abstract
Objective To observe the treatment effect of nucleotide drugs (entecavir) combined with Transhepatic Arterial Chemoem-bolization (TACE) on patients with primary hepatic carcinoma of the HBV-DNA copying. Methods In this research, 64 cases of primary liver cancer patients were randomly divided into treatment group (n=33) and control group (n=31). Patients in the treatment group got TACE combined with entecavir, while patients in the control group were only treated with TACE, not for antiviral treatment. Detect the blood levels of ALT, AST, TBIL, γ-GT, ALB and AFP at 2 and 4 months after treatment in two groups. Detect the serum HBV-DNA levels and HBV activation rate at 1 month after treatment. Compare the survival rates of 6 months, 9 months, 12 months, 18 months after treatment between the two groups. And compare the Child-Pugh score of 3 months, 6 months, 12 months after treatment between the two groups. Results The survival rate at each time point of treatment group was significantly higher than that of the control group (P<0.05). After treatment, the liver function of the two groups both got some recovery. But the liver function recovery was significantly better in treatment group than in the control group (P<0.01). One month postoperatively, the serum HBV activation rate of the treatment group was obviously lower than that of the control group (9.09% vs.32.3%, P<0.05). The Child - Pugh score was also significantly lower in the treatment group than in the control group (P<0.05). Conclusion Nucleotide drugs (entecavir) antiviral treatment can reduce HBV reactivation, improve liver function, and pro-long the survival of liver cancer patients with TACE.关键词
恩替卡韦/原发性肝癌/肝动脉化疗栓塞术/乙肝病毒再激活/抗病毒治疗Key words
Entecavir/Primary hepatic carcinoma/TACE/HBV reactivation/Antiviral therapy分类
医药卫生引用本文复制引用
蒋世海,李万浪,吕永昌,韦金磊,刘阳震..恩替卡韦联合肝动脉化疗栓塞术对肝癌合并乙肝患者的疗效及乙肝病毒再激活的影响[J].肿瘤药学,2018,8(2):215-218,4.基金项目
广西壮族自治区卫生和计划生育委员会自筹经费科研课题(Z2015696). （Z2015696）
